Relative effect sizes of eszopiclone treatment for insomnia in patients with primary insomnia and insomnia co-morbid with major depressive disorder, generalized anxiety disorder, perimenopausal transition or rheumatoid arthritis

被引：0
|
作者：
Schaefer, K.
McCall, W.
Krystal, A.
Rubens, R.
Wilson, P.
Pfleeger, K.
Roth, T.
机构：
[1] Sepracor Inc, Marlborough, MA USA
[2] Wake Forest Univ, Winston Salem, NC 27109 USA
[3] Duke Univ, Durham, NC 27706 USA
[4] Sepracor Inc, Detroit, MI USA
来源：
SLEEP | 2007年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
716
引用
收藏
页码：A243 / A244
页数：2
相关论文
共 50 条
  • [1] Baseline insomnia severity in patients with primary insomnia and insomnia co-morbid with major depressive disorder, generalized anxiety disorder, perimenopausal transition or rheumatoid arthritis
    Roth, T.
    Wilson, P.
    Schaefer, K.
    Rubens, R.
    Walsh, J.
    Krystal, A.
    [J]. SLEEP, 2007, 30 : A247 - A247
  • [2] Insomnia severity in patients with primary insomnia and insomnia co-morbid with major depressive disorder or generalized anxiety disorder
    Roth, Thomas
    Wilson, Phebe
    Schaefer, Kendyl
    Pfleeger, Kimberly
    Rubens, Robert
    Fava, Maurizio
    Pollack, Mark
    [J]. BIOLOGICAL PSYCHIATRY, 2007, 61 (08) : 84S - 85S
  • [3] Evaluation of the Hamilton depression scale following eszopiclone treatment for insomnia in patients with insomnia co-morbid with major depressive disorder or generalized anxiety disorder
    Fava, M.
    Pollack, M.
    Rubens, R.
    Amato, D.
    Kostal, A.
    Hayduk, R.
    McCall, W.
    [J]. SLEEP, 2007, 30 : A329 - A330
  • [4] Evaluation of the Hamilton depression scale following eszopiclone treatment for insomnia in patients with insomnia co-morbid with major depressive disorder or generalized anxiety disorder
    Fava, Maurizio
    Pollack, Mark
    Rubens, Robert
    Amato, David
    Krystal, Andrew
    Hayduk, Roza
    McCall, W. Vaughn
    [J]. BIOLOGICAL PSYCHIATRY, 2007, 61 (08) : 84S - 84S
  • [5] Evaluation of the HAM-D17 following eszopiclone treatment in patients with insomnia co-morbid with major depressive disorder or generalized anxiety disorder
    Montgomery, S.
    Fava, M.
    Krystal, A.
    Wessel, T.
    Amato, D.
    Cooper, J.
    McCall, W. V.
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2008, 11 : 306 - 306
  • [6] Evaluation of the HAM-D17 following eszopiclone treatment in patients with insomnia co-morbid with major depressive disorder or generalized anxiety disorder
    Fava, M.
    Pollack, M.
    Montgomery, S.
    Wessel, T.
    Amato, D.
    Krystal, A.
    Hayduk, R.
    McCall, W. V.
    [J]. EUROPEAN PSYCHIATRY, 2008, 23 : S360 - S360
  • [7] Differential sleep effects of eszopiclone treatment and discontinuation in patients with primary insomnia and insomnia co-existing with major depressive disorder or generalized anxiety disorder
    Krystal, A.
    Schaefer, K.
    Rockett, C.
    Fava, M.
    Amato, D.
    Roth, T.
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2008, 11 : 306 - 306
  • [8] Sleep outcomes following eszopiclone discontinuation in patients with primary insomnia and insomnia co-existing with major depressive disorder or generalized anxiety disorder
    Krystal, A.
    Fava, M.
    Pollack, M.
    Rubens, R.
    Schaefer, K.
    Amato, D.
    Roth, T.
    [J]. SLEEP, 2007, 30 : A245 - A245
  • [9] Differential sleep effects of eszopiclone treatment and discontinuation in patients with primary insomnia and insomnia co-existing with major depressive disorder (MDD) or generalized anxiety disorder (GAD)
    Fava, M.
    Schaefer, K.
    Rockett, C. B.
    Amato, D.
    Roth, T.
    [J]. JOURNAL OF SLEEP RESEARCH, 2008, 17 : 192 - 192
  • [10] Anxiolytic impact of cognitive behavioural therapy for insomnia in patients with co-morbid insomnia and generalized anxiety disorder
    Lau, Parky
    Starick, Elisha
    Carney, Colleen E.
    [J]. BEHAVIOURAL AND COGNITIVE PSYCHOTHERAPY, 2024, 52 (04) : 456 - 460
12345